All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: SCSA-0.2 (for 10mM×0.2ml)

Cat. No.: SCSA-25 (for 25mg)

Cat. No.: SCSA-100 (for 100mg)

Description

Schisantherin A, a dibenzocyclooctadiene lignan derived from the fruit of Schisandra sphenanthera, acts by inhibiting the translocation of p65-NF-κB into the nucleus through the degradation of IκBα.

Basic Information

• Aliases: Gomisin C; Schisantherin A; Wuweizi ester A
• Source: Schisandra sphenanthera Rehd. et Wils.
• Compound type: Phenylpropanoids > Lignans > Dibenzocyclooctene
• Chemical Formula: C₃₀H₃₂O₉
• Molecular Weight: 536.57
• CAS Number: 58546-56-8
• Purity: 98%, HPLC
• Solvent/Solubility: DMSO: ≥ 100 mg/ml (186.37 mM); Water: < 0.1 mg/ml (insoluble)
• Solution Preparation: 10mg dissolved in 1.86ml DMSO, or 5.37mg in 1ml DMSO, to prepare a 10mM solution.

Signaling Pathway

In Vitro Study

The concentrations of TNF-α and IL-6 in the supernatant of cells pretreated with 2.5 or 25 mg/L of Schisantherin A are significantly decreased compared to the LPS control group (p<0.05, p<0.01). The potential cytotoxicity of Schisantherin A is evaluated by the MTT assay after incubating cells for 24 h in the absence or presence of LPS, and the results show that cell viabilities are not affected by the cytokines at concentrations used (0.5, 2.5, 25 mg/L). RAW 264.7 murine macrophage cells are pre-incubated with Schisantherin A for 1 h and then stimulated with 1 mg/L LPS for 12 h. Both LPS and samples are untreated in the control group. After the cell culture media are collected, nitrite and PGE2 levels are determined, and Schisantherin A is found to reduce NO and PGE2 production in a dose-dependent manner.

In Vivo Study

Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to possess various beneficial pharmacological effects. Schisantherin A protects against lipopolysaccharide-induced acute respiratory distress syndrome in mice by inhibiting NF-κB and MAPKs signaling pathways. Pretreatment with Schisantherin A markedly ameliorates LPS-induced histopathologic changes and decreases the levels of TNF-α, IL-6, and IL-1β in the BALF. Additionally, Schisantherin A suppresses the phosphorylation of NF-κB p65, IκB-α, JNK, ERK, and p38 induced by LPS. The lung wet/dry weight ratio is evaluated at 7 h after intranasal instillation of LPS. The results show no differences between the control group and the Schisantherin A (40 mg/kg) group (p>0.05). LPS causes a significant increase in the lung wet/dry weight ratio (p<0.01) compared with the control group. Schisantherin A dose-dependently decreases the lung wet/dry weight ratio (p<0.05) compared to that in the LPS group.

Clinical Trial

N/A

Storage

Store at -20°C for at least one year. The solid powder is stable at 4°C for at least one month. If dissolved in a non-DMSO solvent, it is recommended to aliquot and store at -80°C for up to six months.

Precautions

• This product may have a certain degree of toxicity to the human body. Please take appropriate precautions to avoid direct contact with the body or inhalation.
• This product is for scientific research use only by professionals and is not intended for clinical diagnosis or treatment, food, or pharmaceutical purposes. It should not be stored in ordinary residential areas.
• For your safety and health, please wear laboratory attire and disposable gloves while handling.

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                       Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory